REG
REPORT FROM PILA PHARMA AB'S ANNUAL GENERAL MEETING 2026
PILA PHARMA AB (publ) held its Annual General Meeting today, Tuesday 19 May 2026, at the company's premises at Norra Vallgatan 72 in Malmö. Attorney Krister Hjelmstedt was electe...
PILA PHARMA: UPCOMING INVESTOR EVENTS AND INTERVIEWS - PRESENTING AT REDEYE DIABETES DAY ON 06 MAY
PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company"), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition, today announces that it will have cor...
REG
PILA PHARMA PUBLISHES ITS ANNUAL REPORT FOR 2025
PILA PHARMA AB (publ), (FN STO: PILA), ("PILA PHARMA" or the "Company"), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition, announces that its A...
REG
MAR
PILA PHARMA: UPDATE TO PRECLINICAL RAT OBESITY STUDIES - LOW EXPOSURE OF XEN-D0501 COULD EXPLAIN LACK OF EFFECT ON BODYWEIGHT
PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company"), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition, today announces that drug exposure in...
REG
KALLELSE TILL ÅRSSTÄMMA I PILA PHARMA AB
Aktieägarna i PILA PHARMA AB (publ), org.nr 556966-4831, ("PILA PHARMA" eller "Bolaget") kallas härmed till årsstämma tisdagen den 19 maj 2026, kl. 15.00 i Bolagets lokaler på No...
PILA PHARMA CLARIFIES: DECISION TO POSTPONE THE ANNUAL REPORT TO AWAIT CONCLUSION ON PRECLINICAL OBESITY STUDIES
PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") yesterday announced that the publication of the annual report for the 2025 fiscal year and the date for the annual general...
REG
PILA PHARMA POSTPONES THE PUBLICATION OF THE ANNUAL REPORT AND THE ANNUAL GENERAL MEETING
PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") announces that the publication of the annual report for the 2025 fiscal year will be postponed.
The annual report is at an...
PILA PHARMA: TO PARTICIPATE IN PHARMA PARTNERSHIP CONFERENCE BIO EUROPE SPRING IN LISBON, MARCH 23-25
PILA PHARMA AB (publ) (FN STO: PILA) ("PILA" or the "Company"), an innovative biotech company developing a novel oral drug based on TRPV1 inhibition, today shares its participati...
PILA PHARMA: TO2 WARRANTS CONVERTED, SHARES ARE NOW TRADABLE - CEO & FOUNDER'S PARTICIPATION DISCLOSED
PILA PHARMA AB (publ) (FN STO: PILA) ("PILA" or "the Company"), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition, informs of the conversion of...
PILA PHARMA: MANAGEMENT TEAM COMMENTS ON OUTCOME OF TO2 WARRANTS
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition, today announced the outcome of exercise in warrants of...
REG
MAR
PILA PHARMA ANNOUNCES THE OUTCOME IN THE EXERCISE OF WARRANTS OF SERIES TO2
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEA...
REG
PILA PHARMA: Upcoming last days for exercise with the warrants of series TO2
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEA...
PILA PHARMA: CEO REPORT INTERVIEW AND Q&A ON CLINICAL PLANS, TO2 WARRANTS AND MORE, AVAILABLE FOR REPLAY NOW
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition, invites to a live online interview and Q&A.
CEO Gustav...
PILA PHARMA: INVITATION TO LIVE H2 / YEAR-END REPORT INTERVIEW AND Q&A TODAY AT 14:00 CET
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition, invites to a live online interview and Q&A.
CEO Gustav...
REG
PILA PHARMA AB (publ) (FN STO: PILA) today publishes the Company´s year-end report for the period January - December 2025.
The report can be found on the Company´s website:
https://pilapharma.com/financial-reports/SUMMARY OF YEAR-END REPORT
SECOND HALF YEAR (1 JULY- 31 DECEMBER 2025)
• Operating i...
REG
MAR
PILA PHARMA PREPARES CLINICAL TRIAL APPLICATION IN RARE DISEASE ERYTHROMELALGIA
PILA PHARMA AB (publ) (FN STO: PILA) ("PILA PHARMA" or the "Company"), an innovative biotech company developing a novel oral, small molecule TRPV1 inhibitor, today announces that...
REG
THE EXERCISE PRICE FOR THE WARRANTS OF SERIES TO2 IN PILA PHARMA HAS BEEN DETERMINED TO SEK 1.50 AND THE EXERCISE PERIOD COMMENCES TODAY
PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company"), an innovative biotech company developing a novel oral, small molecule TRPV1 inhibitor, completed a rights issue of units d...
REG
PILA PHARMA ACCELERATES THE PUBLICATION OF THE INTERIM REPORT OF THE SECOND HALF OF 2025
PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company"), an innovative biotech company developing a novel oral, small molecule TRPV1 inhibitor, today announced that it will publis...
Om PILA PHARMA
Prenumerera
Få löpande information från PILA PHARMA via e-post.
Handelsinformation
Kurs 1,55 SEK (2026-05-27)
Förändring −50,79% (2025-05-27)